Suxamethonium Chloride

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Suxamethonium chloride dihydrate 5%{relative} (plus 5% overage added to formulation);  

Pieejams no:

Max Health Limited

SNN (starptautisko nepatentēto nosaukumu):

Suxamethonium chloride dihydrate 5% w/v (plus 5% overage added to formulation)

Deva:

50 mg/mL

Zāļu forma:

Solution for injection

Kompozīcija:

Active: Suxamethonium chloride dihydrate 5%{relative} (plus 5% overage added to formulation)   Excipient: Hydrochloric acid Nitrogen Water for injection

Vienības iepakojumā:

Ampoule, glass, 2 mL clear Type I, 10 dose units

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

Mac Chem Products (India) Pvt. Ltd.

Ārstēšanas norādes:

For the production of skeletal muscle relaxation in anesthesia. Suited for procedures requiring only brief relaxation such as endotracheal intubation, endoscopic examinations, orthopaedic manipulations, short surgical procedures and electro-convulsive therapy.

Produktu pārskats:

Package - Contents - Shelf Life: Ampoule, glass, 2 mL clear Type I - 10 dose units - 18 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light

Autorizācija datums:

2011-04-29

Produkta apraksts

Page 1 of 8
NEW ZEALAND DATA SHEET
1. PRODUCT NAME
S
uxamethonium Chloride 50 mg/mL
solution for injection.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 2 mL of solution contains 100 mg of suxamethonium chloride.
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Solution for Injection or Infusion. Clear, colourless solution.
pH of the solution 3.0-4.2.
Osmolality of the product is 300-365 mOsmol/kg.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the production of skeletal muscle relaxation in anaesthesia.
Suited for procedures requiring only
brief
relaxation
such
as
endotracheal
intubation,
endoscopic
examinations,
orthopaedic
manipulations, short surgical procedures and electro-convulsive
therapy.
4.2 DOSE AND METHOD OF ADMINISTRATION
Dosage is individualised and its administration should be determined
after careful assessment of the
patient. The dose of suxamethonium is dependent on bodyweight, the
degree of muscle relaxation
required and the response of individual patients. Suxamethonium causes
paralysis of the respiratory
muscles, therefore after administration, respiration must be
controlled. It should not be administered
to a conscious patient.
Suxamethonium should not be mixed with any neuromuscular blocking
agent, nor with general
anaesthetics such as short acting barbiturates, nor any other
therapeutic agent in the same syringe.
Suxamethonium Chloride contains no antimicrobial agent. It should be
used only once and any residue
discarded.
An initial test dose of 0.1 mg/kg may be given intravenously to
determine the patient’s response.
ADULT
For short procedures, such as endotracheal intubation the usual adult
dose is 0.6 mg/kg (range 0.3-
1.1 mg/kg) administered IV over 10 to 30 seconds. This dose produces
muscle relaxation in about 60
seconds and has a duration of approximately 4 to 6 minutes. Larger
doses produce more prolonged
muscle relaxation.
For more prolonged surgical procedures in an adult, suxamethonium is
commonly given by IV infusion
at a rate of 2.5 -4.3 mg